Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
AFT Leaves X Over AI-Generated Images of Minors 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
CAMBRIDGE, Mass., March 31, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective March 31, 2017, as part of Russell’s quarterly additions of companies with recent initial public offerings.
The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10 percent of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes. The Russell Microcap® Index represents 2,000 small cap and micro-cap stocks that captures the smallest 1,000 companies in the Russell 2000®, in addition to 1,000 smaller U.S.- based listed stocks.
Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Russell Investments determines membership for each index based on objective market capitalization rankings and style attributes.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. For more information, please visit http://jouncetx.com/
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
